Value
5.0/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 4.2 |
| P/S | 3.7 |
| Fwd P/E | 4.6 |
| PEG | 6.3 |
| Analyst target | 6.0 |
- ▸Forward P/E: 27.1x
- ▸PEG: 1.18
ARGX · Why this verdict
Why argenx (ARGX) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score7.1/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
argenx is a high-quality biotech with 52% revenue growth, 32% margins, a wide moat and a 9/9 Piotroski score; the main hesitation is a 26.8x forward P/E and a reward-to-risk of 1.33 that has not yet produced a breakout.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business earns strong margins of 32%, holds a wide economic moat and scores 9/9 on the Piotroski F-Score, with an overall quality score of 9.2. Quality breakdown | Margins stay near 32% and the Piotroski score remains at 8 or higher. | →Stable |
| CounterBiotech moats rest on a few products and patents, and competing drugs could erode margins quickly. | ||
Revenue is growing 52% year over year, with growth scoring a perfect 10.0 out of 10. Growth breakdown | Revenue growth stays above 30% over the next 12 months. | →Stable |
| CounterGrowth of this pace is hard to sustain as the base grows, and a deceleration would hit a premium multiple. | ||
The stock trades at a forward P/E of 26.8x with a PEG of 1.20, so expectations for growth are already substantial. Valuation breakdown | Earnings growth catches up so forward P/E falls below 22x at a flat price. | ↓Deteriorating |
| CounterA PEG of 1.20 for a company growing 52% with 32% margins may still be reasonable versus peers. | ||
Analyst upside is 15.7% against 11.8% downside, a reward-to-risk of 1.33 that is positive but modest for a speculative biotech. Estimated upside | Price pulls back or targets rise so reward-to-risk exceeds 1.5. | →Stable |
| CounterThe analyst upside of 29% before haircut suggests analysts see more room than the conservative target implies. | ||
Price is above the 200-day average with rising OBV volume accumulation, a momentum score of 6.9 and a perfect MACD component. Momentum breakdown | Momentum stays above 5.5 and a breakout above resistance occurs. | ↑Improving |
| CounterThe technical setup has not yet produced a breakout above resistance, and the stock sits above max pain of $340, which can pull price lower into expiry. | ||
The business earns strong margins of 32%, holds a wide economic moat and scores 9/9 on the Piotroski F-Score, with an overall quality score of 9.2.
→StableQuality breakdown
- Expectation
- Margins stay near 32% and the Piotroski score remains at 8 or higher.
CounterBiotech moats rest on a few products and patents, and competing drugs could erode margins quickly.
Revenue is growing 52% year over year, with growth scoring a perfect 10.0 out of 10.
→StableGrowth breakdown
- Expectation
- Revenue growth stays above 30% over the next 12 months.
CounterGrowth of this pace is hard to sustain as the base grows, and a deceleration would hit a premium multiple.
The stock trades at a forward P/E of 26.8x with a PEG of 1.20, so expectations for growth are already substantial.
↓DeterioratingValuation breakdown
- Expectation
- Earnings growth catches up so forward P/E falls below 22x at a flat price.
CounterA PEG of 1.20 for a company growing 52% with 32% margins may still be reasonable versus peers.
Analyst upside is 15.7% against 11.8% downside, a reward-to-risk of 1.33 that is positive but modest for a speculative biotech.
→StableEstimated upside
- Expectation
- Price pulls back or targets rise so reward-to-risk exceeds 1.5.
CounterThe analyst upside of 29% before haircut suggests analysts see more room than the conservative target implies.
Price is above the 200-day average with rising OBV volume accumulation, a momentum score of 6.9 and a perfect MACD component.
↑ImprovingMomentum breakdown
- Expectation
- Momentum stays above 5.5 and a breakout above resistance occurs.
CounterThe technical setup has not yet produced a breakout above resistance, and the stock sits above max pain of $340, which can pull price lower into expiry.
Per-dimension breakdown
Quality
9.2/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 8.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Moat | 8.0 |
| Piotroski F | 10.0 |
- ▸Strong margins: 32%
- ▸Wide economic moat
- ▸Strong Piotroski F-Score: 9/9
- ▸High-quality business
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 52% YoY
Momentum
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 4.9 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 8.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 23%
Insider
5.0/10data confidence 50%Peer rank
7.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.4 |
| quality rank | 7.8 |
| growth rank | 7.4 |
- ▸Conservative debt levels
Technical
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.2 |
| support resistance | 0.1 |
| 52w position | 7.4 |
| gap | 5.0 |
Risk (lower is worse)
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 7.4 |
| volatility | 4.9 |
| put call | 6.8 |
| implied vol | 6.1 |
| max pain risk | 3.0 |
| debt equity | 10.0 |
- ▸Above max pain $340
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.18, quality 9.2/10, growth 10.0/10).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|ENTRY_STICKY:WITHIN_BANDPassed (7)
- MOMENTUM:7.4>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:113d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (0)
none
Reward-to-Risk
0.72
Upside
+10.9%
Downside
15.0%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 9.2 and growth 10.0 both clear their thresholds, with asymmetric R:R of 0.72 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 9.2, and Catalyst at 7.5; the weakest are Technical at 3.2, Insider at 5.0, and Value at 5.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.72 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Hypergrowth Revenue Expansion
Trip ifRevenue growth falls below 25% year over year.
- P2High Quality Wide Moat
Trip ifNet margin falls below 20% from current 32%.
- P3Premium Valuation Risk
Trip ifForward P/E rises above 35x from current 26.8x.
- P4Analyst Upside Moderate Asymmetry
Trip ifReward-to-risk falls below 1.0 from current 1.33.
- P5Uptrend Volume Accumulation
Trip ifMomentum score falls below 4.5 from current 6.9.